QUOTIENT-SCIENCES
Quotient Sciences , a leading drug development services organization, has significantly expanded its formulation development and clinical trial manufacturing operations at its Reading, U.K., facility. The program’s investment has tripled the site’s GMP capacity, added new equipment for solid oral dose manufacturing and significantly increased staffing levels.
“Our investment in Reading is in direct response to increasing client demand,” said Mark Egerton , CEO of Quotient Sciences. “With drug development expertise on both sides of the Atlantic, we are optimally positioned to serve our global client base. The Reading site can support customers with stand-alone formulation and clinical trial manufacturing services that can also be integrated into Translational Pharmaceutics® programs.”
Activities at the 48,000-square-foot Reading facility are focused on small molecule drug products for oral and inhaled delivery spanning drug substance characterization, formulation development and clinical trial manufacturing. The site routinely handles poorly soluble compounds and is equipped with a broad range of technologies including spray drying, hot melt extrusion, lipidic systems and micronization.
Its capacity is bolstered by 13 GMP manufacturing suites to support traditional Phase I-III clinical trial manufacturing and Translational Pharmaceutics programs that integrate real-time adaptive manufacturing and clinical research. This flexible and nimble approach allows batch sizes to be tailored to the precise needs of a clinical trial. Drug products are rapidly supplied into global patient trials and clinical pharmacology units, delivering substantial benefits to customers including flexible dose adjustments, reductions in manufacturing costs and shorter manufacturing lead times.
Quotient has more than 800 employees across six operating sites in the U.K. and U.S., serving a global customer base of more than 150 biotech and pharma clients.
About Quotient Sciences
Quotient Sciences, a global pharmaceutical development, clinical pharmacology and clinical and commercial manufacturing organization, delivers innovative, customized solutions for pharmaceutical and biotech customers through both individual and integrated services. Its Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research for the continuous improvement of drug development programs, and is proven to accelerate timelines and reduce cost. Visit quotientsciences.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181105005087/en/
Contact:
SCORR Marketing Jane Byram, +1-512-626-2758 jane@scorrmarketing.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hanshow Showcases Retail Media and Store Intelligence at 2025 CGF Global Summit19.6.2025 17:00:00 CEST | Press release
Hanshow, a global leader in digital retail solutions, underscored its leadership in AI, IoT, and Retail Media at the 2025 Global Summit of the Consumer Good Forum (CGF), held from June 11 to 13 at RAI Amsterdam. From an immersive ‘Future Store’ showcase in the I-Zone to moderating one of the Summit’s most anticipated panel discussions, Hanshow demonstrated how its integrated platform is driving the next wave of store transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619798164/en/ Inside the Future Store: Hanshow’s Real-Time Innovation at I-Zone At Booth No.8 in the I-Zone, Hanshow presented an interactive showcase themed “Powering Your Future Store,” highlighting four core pillars of the future store: real-time pricing and shelf operations powered by ESLs; smart carts that enhance the shopping experience with autonomous navigation and seamless checkout; GenAI-enabled journeys offering contextual promotions an
Grid Dynamics to Unveil Robotic Inspection Solution at Automatica 202519.6.2025 15:15:00 CEST | Press release
Key Takeaways: At Automatica 2025, Grid Dynamics will present TPGen—an AI robotic solution developed in partnership with Wandelbots to automate industrial robotic workflows that involve complex programming. The new solution dramatically reduces programming time—transforming what typically takes weeks of manual robot programming and analysis into automated processes completed in minutes through automatic tool-path generation based on CAD models. TPGen is built on top of the Wandelbots NOVA platform which enables seamless integration with a broad range of robotic manipulators. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics)—a leading provider of technology consulting, platform and product engineering, AI, and digital‑engagement services—today announced it will showcase its TPGen robotic solution at Automatica 2025, the world's leading event for smart automation and robotics taking place in Munich, Germany from June 24-27, 2025. The TPGen solution from Grid Dynamics, developed
Experian Accelerates Migration to AWS to Drive Innovation with Generative AI19.6.2025 15:00:00 CEST | Press release
Global data and technology leader expands its cloud footprint to enhance performance and reliability, using AWS analytics and AI capabilities to give financial organizations access to real-time intelligence Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Experian, a global data and technology company, is embarking on the next phase of its cloud migration and has selected AWS as its preferred cloud. By leveraging AWS’s advanced cloud capabilities, Experian can provide faster, more scalable solutions that empower clients with deeper insights and more secure data services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619029263/en/ Experian's cloud first strategy, in partnership with AWS, accelerates innovation by enhancing performance, scalability, and reliability, while enabling the company to better serve its clients with innovative products and solutions. By migrating of
Greenland Resources Receives 30-Year Exploitation License for Molybdenum and Magnesium19.6.2025 14:52:00 CEST | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) and its fully owned Greenlandic subsidiary Greenland Resources A/S (“Greenland Resources” or the “Company”) is pleased to announce that today the Greenland’s Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, together with Dr. Ruben Shiffman, Chairman of the Board of Directors of Greenland Resources, signed a 30-year exploitation permit for molybdenum and magnesium for the Company’s Malmbjerg project in east Greenland (now defined as the Piiaaffik Høstakken). The Company can apply to extend the licence period up to 50-years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250619915614/en/ Naalakkersuisut's Minister for Business, Mineral Resources, Energy, Justice and Gender Equality, Naaja H. Nathanielsen, stated at the handover ceremony: "It is with great satisfaction that the Greenland Government can grant another exploit
Ares Management Launches First ELTIF to Expand Access to European Direct Lending Strategy19.6.2025 12:00:00 CEST | Press release
Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today the launch of its first European Long-Term Investment Fund (“ELTIF”) vehicle, the Ares European Strategic Income ELTIF Fund (“AESIF ELTIF”), a semi-liquid perpetual direct lending fund that will provide individual investors in the European Economic Area with expanded access to Ares’ leading European Direct Lending strategy. AESIF ELTIF is the latest offering through the wealth channel and its first under the updated ELTIF regime. Designed to deliver a diversified portfolio largely comprising directly originated, senior secured floating rate loans to businesses in Western Europe, AESIF ELTIF seeks to provide a durable income solution with downside protection and yield stability. AESIF ELTIF is intended to widen individual investor participation in Ares’ European Direct Lending strategy through lower investment minimums relative to traditional alternative investment product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom